Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole versus risperidone for social cognition in schizophrenia
NL-OMON26432Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in schizophrenia comparing Aripiprazole with Risperidone (2 arms). Primary endpoints: Effect on social cognitive processes and Comparative efficacy against social cognitive deficits. Started Dec 2005; status: active, not recruiting.
02
Drugs
aripiprazolerisperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NL-OMON26432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26432.